Replies to post #222730 on NorthWest Biotherapeutics Inc (NWBO)

[marzan]

Johns Hopkins endorses DcVax L as SOC is huge. They are also doing gbm research. It is good to get recognized from an equally talented research group. I think helmet is gone. Dr. Stupps will probably be staying low profile.

[GoodGuyBill]

Shouldn't this be 2.1%?

Only 21% of patients had grade 3 or 4 adverse events. The results of this Phase III clinical trial show promising feasibility of integrating DCV into standard therapy and suggests a survival benefit [214]."

[maverick_1]

The results of this Phase III clinical trial show promising feasibility of integrating DCV into standard therapy and suggests a survival benefit [214]."

A Characterization of Dendritic Cells and Their Role in Immunotherapy in Glioblastoma: From Preclinical Studies to Clinical Trials
Siddhartha Srivastava †,Christina Jackson †OrcID,Timothy Kim,John Choi and Michael Lim *
Department of Neurosurgery, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA

* Correspondence: [e-mail]; Tel.: [phone]
† These authors share equal contribution.https://www.mdpi.com/2072-6694/11/4/537/htm

Michael Lim, M.D.
Photo of Dr. Michael Lim, M.D.
Director of Brain Tumor Immunotherapy
Professor of Neurosurgery
Male

Languages: English, Korean

Expertise: Arteriovenous Malformations (AVM), Brain Cancer, Brain Tumors, Glioblastoma, Metastatic Brain Tumors, Neurosurgery, Neurosurgical Oncology, Radiosurgery, Skull Base Surgery, Skull Base Tumors, Trigeminal Neuralgia, Von Hippel-Lindau (VHL) ...read less

Research Interests: Brain Tumor Vaccines; Brain Metastases; Trigeminal Neuralgia; Spine Radiosurgery

Research & Publications
PubMed ResearchGate
Research Summary
Dr. Lim's primary research interest involves immune-based therapies against brain tumors. His research focuses on understanding the mechanisms of immune evasion by primary brain tumors with the goal of translation to novel therapies against gliomas. Dr. Lim also performs clinical research. He publishes extensively in radiosurgery and also has interests in brain tumor clinical trials for which he works closely with the neuro-oncologists in a team approach.

Lab
Dr. Lim is the Director of the Brain Cancer Immunology Laboratory at Johns Hopkins. His laboratory explores mechanisms of immune resistance and novel therapies for brain tumors. In addition, his laboratory performs translational studies to develop the next generation of clinical trials.

Dr. Lim is the co-principal investigator of the Johns Hopkins Comprehensive Subependymoma and Ependymoma Research Center. This research center conducts basic science, translational and clinical practice research with the goals of optimizing current treatment options and developing new therapies that will positively impact the care and lives of patients with subependymomas and ependymomas, primary central nervous system (CNS) brain tumors
https://www.hopkinsmedicine.org/profiles/results/directory/profile/0022118/michael-lim

DIFFERENT STROKES FOR DIFFERENT FOLKS